Valion Bio, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
Dean Zikria, a current board member, was appointed Interim CEO effective September 22, 2026, at $23,333/month plus 50,000 RSUs (with another 50,000 RSUs contingent on equity plan increase) vesting quarterly over 12 months, plus discretionary bonus upon strategic transaction closing. Thomas Jensen became Board Chair; Sheryle Bolton departed. Zikria's agreement expires January 22, 2027, with option to extend 12 months; he must step down from all committees during engagement and cannot serve as independent director.
Why this rating
Interim CEO appointment is material for a $4M company (15% annual cost burn vs. market cap). Leadership continuity risk and execution uncertainty offset by experienced insider. Modest compensation cost; RSU dilution contingent.
Price action (we called it neutral)
before filing · preread $2.55 ▲ 4.08% | at our read · unknown $2.45 | +10 min · unknown $2.54 ▲ 3.88% | +30 min · unknown $2.26 ▼ 7.88% | +1 hr pending | +4 hrs pending |
The stock had already moved -3.92% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.